Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Merkel Cell Carcinoma of Skin

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dermato-oncology Department, Ambroise Paré Hospital, APHP

Boulogne-Billancourt, 92100, France

Location status: Recruiting

About this study

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients >= 18 years old;
Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
Informed for the study and no-opposed for participation;
Affiliated with a social security scheme or in an equivalent situation.

Exclusion criteria

Patients ongoing another interventional clinical trial;
Patients under guardianship or trusteeship;
Pregnancy or breastfeed;
Patients refusal.

Treatment and study plan

Primary outcomes

Anti-MCPyV functionality

Time frame: Day 0 and Day 4

Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.

Study contacts

Contact information is provided by the study sponsor or research team.

Astrid Blom, MD

CONTACT

[email protected]

+33 (01) 49 09 44 82

Yassine Taoufik, MD, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Official study title

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin

Acronym: VIRASKIN

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Jan 17, 2025
Registry last updated: Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting